Current therapies focused on high-density lipoproteins associated with cardiovascular disease

Diego Estrada-Luna, María Araceli Ortiz-Rodriguez, Lizett Medina-Briseño, Elizabeth Carreón-Torres, Jeannett Alejandra Izquierdo-Vega, Ashutosh Sharma, Juan Carlos Cancino-Díaz, Oscar Pérez-Méndez, Helen Belefant-Miller, Gabriel Betanzos-Cabrera

Research output: Contribution to journalScientific review

8 Scopus citations


© 2018 by the authors. High-density lipoproteins (HDL) comprise a heterogeneous family of lipoprotein particles divided into subclasses that are determined by density, size and surface charge as well as protein composition. Epidemiological studies have suggested an inverse correlation between High-density lipoprotein-cholesterol (HDL-C) levels and the risk of cardiovascular diseases and atherosclerosis. HDLs promote reverse cholesterol transport (RCT) and have several atheroprotective functions such as anti-inflammation, anti-thrombosis, and anti-oxidation. HDLs are considered to be atheroprotective because they are associated in serum with paraoxonases (PONs) which protect HDL from oxidation. Polyphenol consumption reduces the risk of chronic diseases in humans. Polyphenols increase the binding of HDL to PON1, increasing the catalytic activity of PON1. This review summarizes the evidence currently available regarding pharmacological and alternative treatments aimed at improving the functionality of HDL-C. Information on the effectiveness of the treatments has contributed to the understanding of the molecular mechanisms that regulate plasma levels of HDL-C, thereby promoting the development of more effective treatment of cardiovascular diseases. For that purpose, Scopus and Medline databases were searched to identify the publications investigating the impact of current therapies focused on high-density lipoproteins.
Original languageAmerican English
StatePublished - 23 Oct 2018


Cite this

Estrada-Luna, D., Ortiz-Rodriguez, M. A., Medina-Briseño, L., Carreón-Torres, E., Izquierdo-Vega, J. A., Sharma, A., Cancino-Díaz, J. C., Pérez-Méndez, O., Belefant-Miller, H., & Betanzos-Cabrera, G. (2018). Current therapies focused on high-density lipoproteins associated with cardiovascular disease. Molecules.